Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Immunotherapy. Royal Victoria Hospital, Montreal, QC, Canada



Survival: 10.0 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
Immunotherapy
   
Drugs:
Country: Canada
   
City/State/Province: Montreal, QC
   
Hospital: Royal Victoria Hospital
   
Journal: Link
   
Date: 7/2011

Description:
Patients:
This phase II study involved advanced non-small-cell lung cancer patients who had not received prior chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 420 patients with a median age of 62 years and 65% male. Group B had 408 patients with a median age of 61 years and 66% male.

Treatment:
Patients in group A were treated with the chemotherapy agents paclitaxel and carboplatin.

Patients in group B were treated with paclitaxel and carboplatin, as well as the immunotherapy agent called PF-3512676, which triggers a protein called TLR9 to stimulate an antitumor immune response.

Toxicities:
Treatment-related deaths due to infection were reported for group A. Grade 3 or higher neutropenia, leukopenia, lymphopenia, and thrombocytopenia were also reported.

Treatment-related deaths were reported for group B; causes included pulmonary embolism and infection. Grade 3 or higher injection-site reactions, such as pain and swelling, were also reported.

Results:
The median overall survival rates for groups A and B were 9.8 and 10.0 months, respectively.

Support:
This study was supported by Pfizer, Inc.

Correspondence: Dr. Vera Hirsh; email: vera.hirsh@muhc.mcgill.ca

E-mail to a Friend Email Physician More Information